文献速递肾癌与肾肿瘤

体质指数对肾癌预后影响的系统综述与荟萃分析

A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes.
PubMed 文献 · J Urol · 2020-09-18

该系统综述与荟萃分析纳入34项研究共50717例患者,评估体质指数(BMI)与肾癌结局的关联。结果显示超重和肥胖患者的总生存、癌症特异性生存和无进展生存均优于正常BMI者,而低体重患者癌症特异性生存更差,但研究异质性大,需前瞻性研究验证。

要点

  • 超重/肥胖与肾癌患者更好的癌症特异性生存相关(HR 0.85,95%CI 0.79-0.93)。
  • 低体重患者癌症特异性生存更差(HR 2.16,95%CI 1.15-4.04)。
  • 研究异质性大,结论需多中心前瞻性研究及机制研究确认。

核心结论

  • BMI对肾癌结局呈现有利效应,支持“肥胖悖论”现象,但受研究异质性限制。

主要发现

  • 超重和肥胖患者较正常BMI者癌症特异性生存改善(HR 0.85,95%CI 0.79-0.93)。
  • 无进展生存(HR 0.68,95%CI 0.59-0.78)和总生存(HR 0.66,95%CI 0.55-0.79)呈现类似趋势。
  • 低体重组癌症特异性生存更差(HR 2.16,95%CI 1.15-4.04)。

临床怎么用

  • 临床评估肾癌预后时可参考BMI,但不应仅凭BMI改变治疗决策。

局限性

  • 多数研究为回顾性设计。
  • 研究人群、BMI分类和多变量分析协变量存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Obesity is a well-known risk factor for kidney cancer incidence. However, a number of studies have demonstrated more favorable kidney cancer prognosis in patients with elevated body mass index conferring a survival advantage, termed the "obesity paradox." We aimed to evaluate the association between body mass index and kidney cancer outcomes (progression-free survival, cancer specific survival and overall survival). MATERIALS AND METHODS: A computerized systematic search of Medline®, Embase®, ProQuest®, PubMed® and Google Scholar™ for literature published in English was performed between its inception and December 2018, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used for reporting. RESULTS: Overall, 34 publications comprising a total of 50,717 patients were included in the analysis. The majority assessed the association between body mass index and cancer specific survival. Overweight and obese patients were associated with improved cancer specific survival compared to patients with normal body mass index (HR 0.85, 95% CI 0.79-0.93). A similar trend was demonstrated for progression-free survival (HR 0.68, 95% CI 0.59-0.78) and overall survival (HR 0.66, 95% CI 0.55-0.79). On the contrary, the underweight group was associated with inferior cancer specific survival (HR 2.16, 95% CI 1.15-4.04). Main drawbacks limiting the interpretation were the retrospective design in the majority of studies, heterogeneity in study population, body mass index classification and covariates in multivariate analysis. CONCLUSIONS: This is the largest systematic review evaluating the potential phenomenon of the obesity paradox in kidney cancer outcomes. It demonstrated a favorable effect of body mass index on kidney cancer outcomes. However, due to significant heterogeneity of studies, multicenter prospective studies and further research on the fundamental biological mechanisms are warranted to confirm the significance of body mass index on kidney cancer prognosis.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kim LH, Doan P, He Y, et al. A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes. J Urol. 2020. PMID: 32945696. doi:10.1097/JU.0000000000001377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。